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Abstract
Cost-effective HIV prevention programs should target persons at high risk of HIV acquisition. We conducted an observational
HIV incidence cohort study in Kisumu, Kenya, where HIV prevalence is triple that of the national rate. We used referral and
venue-sampling approaches to enroll HIV-negative persons for a 12-month observational cohort, August 2010 to September
2011, collected data using computer-assisted interviews, and performed HIV testing quarterly. Among 1292 eligible persons,
648 (50%) were excluded for HIV positivity and other reasons. Of the 644 enrollees, 52% were women who were significantly
older than men (P < .01). In all, 7 persons seroconverted (incidence rate [IR] per 100 person-years ¼ 1.11; 95% confidence inter-
val [CI] 0.45-2.30), 6 were women; 5 (IR ¼ 3.14; 95% CI 1.02-7.34) of whom were 25 years. Most new infections occurred in
young women, an observation consistent with other findings in sub-Saharan Africa that women aged 25 years are an important
population for HIV intervention trials in Africa.
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Introduction
Successful HIV prevention trials, similar to successful
programmatic strategies to address HIV acquisition, require the
identification and engagement of persons at risk for HIV
infection.1,2 To detect intervention effectiveness without cost-
prohibitive large sample sizes or very lengthy studies, clinical
prevention trials are usually conducted in populations with high
incidence of diseases targeted by the biomedical intervention.
Recent HIV prevention trials, for example, have been done in
settings with HIV incidence rates (IRs) of 3% to 6%.3-6 Orga-
nizing such trials in the United States, where the overall HIV
incidence is 0.02%,7 has required finding and enrolling subpo-
pulations at markedly increased risk, some of whom may be
socially marginalized, stigmatized, and/or challenging to reach
and retain.8 The US domestic HIV prevention trials can
therefore be labor intensive and expensive.9 In Africa, where
two-thirds of persons living with HIV reside,10 the identification
of populations with high HIV IRs should theoretically be easier.
But several trials have found unexpectedly low incidence in a
context of high prevalence,11-13 the reasons for which have not
always been satisfactorily explained.1
Despite these challenges, several biomedical modalities using
antiretroviral drugs, including 1 vaccine, have been shown in
recent years to be partially effective in reducing HIV infec-
tion.3,4,14-16 When and if such modalities are adopted as national
standards of care, however, the ethical imperative to offer them
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to control group participants in future trials will likely lower the
HIV incidence, this in turn will increase the study sample size
needed to detect the efficacy of new interventions.17 In the cur-
rent global economic environment where resources for HIV pro-
grams are already constrained,18 the adoption of partially
effective interventions may unavoidably create concomitant
fiscal and logistic challenges to improving these interventions.
In this context, the need to identify high-incidence populations
is crucial for both HIV prevention trials and HIV prevention
programs focused on interrupting HIV transmission.
Nyanza province in northwest Kenya has an overall HIV
prevalence of 15%, the highest in the country.19 A recent
serosurvey among adults in its largest city, Kisumu, reported
a prevalence of 26%, 3 times that of the national HIV preva-
lence estimate.20 In preparation for future HIV prevention
trials, the Kenya Medical Research Institute (KEMRI)/Centers
for Disease Control and Prevention (CDC) enrolled 625 sexu-
ally active residents of Kisumu aged 18 to 34 years in the
Kisumu Incidence Cohort Study21 (KICoS) 1, beginning in
January 2007, and 206 adolescents aged 16 to 17 years in
KICoS2, beginning in April 2009.22 As the overall HIV inci-
dence in KICoS1 (1.41% overall; 2.59% among women and
0.59% among men)23 was unexpectedly low relative to the high
prevalence, we initiated KICoS3 to better target individuals at
higher risk for acquiring HIV than KICoS1—which had
recruited using mobilization strategies targeting the general
community (eg, discussions and/or presentations at market
centers, churches, women’s groups, community groups, formal
and informal work-based groups, colleges and schools, and
voluntary counseling and testing centers).
Several studies in sub-Saharan Africa have shown commer-
cial sex work,24 age, gender, marital status, number of sex part-
ners,25-28 genital herpes (Herpes simplex virus [HSV-2])
seropositivity,25,28 reported sexually transmitted infections
(STIs),25 lack of condom use,25,27,29 and alcohol use during sex27
to be among behavioral risk factors associated with acquiring
HIV. We used this knowledge, including information gained
from a formative study conducted to identify strategies to recruit
persons at high risk for HIV infection2 in western Kenya to guide
our recruitment for KICoS3. We sought to (1) identify HIV pre-
valence among screened persons, (2) determine HIV incidence
among enrolled participants, (3) assess differences in the inci-
dence by sex and age among enrolled persons, and (4) examine
demographic and behavioral differences between our initial




Similar to KICoS1, KICoS3 was an observational, prospective
cohort study following individual participants for 12 months23
but using modified eligibility criteria and recruitment methods
described subsequently. Kisumu Incidence Cohort Study 3
accrual occurred during March 2010 to August 2010 with a
12-month routine study follow-up ending in September 2011.
Based on a Poisson distribution, an enrollment sample size of
625 high-risk cohort participants in Kisumu, projected an inci-
dence of 3.0% and retention of 500 (80%); we expected at least
15 HIV seroconverters and a statistically significant result
around the incidence.
Setting
Kisumu is a city of approximately 504 000 people located in
Nyanza Province, Kenya.30
Ethical Review
The study protocol, consent forms, and data collection instru-
ments for this study were reviewed and approved by the
KEMRI Scientific Steering Committee Ethical Review Com-
mittee as well as by the US CDC Institutional Review Board.
Written informed consent was completed by persons meeting
the prescreening eligibility criteria before taking part in data
and specimen collections. Options were provided to complete
the informed consent process and data collection in Dholuo,
English, or Kiswahili.
Recruitment
A participant referral approach, a modification of respondent-
driven sampling,31 was employed to amplify recruitment stra-
tegies identified in the formative study2: initial study recruits
(referred to as seed recruits) were asked to refer those they
knew, who in turn referred those they knew (referred to as off-
spring recruits). Seed enrollees were recruited from a variety of
different venues, including bars, night clubs, market centers,
truck stops, fish landing beaches, churches, women’s groups
and community groups, formal and informal work-based
groups, colleges and schools, and HIV voluntary counseling
and testing centers.
Prescreening, Screening, and Enrollment
Prescreening, informed consent, screening, and enrollment pro-
cedures were conducted at the study facility, the KEMRI-CDC
Clinical Research Center on the campus of the New Nyanza
Provincial General Hospital. Prescreening assessment was
conducted using interviewer-administered computer-assisted
personal interview (CAPI). Persons who met the prescreening
criteria received detailed information about the study prior to
providing written informed consent to proceed with screening
procedures. At screening, a baseline behavioral questionnaire
was administered using audio computer-assisted self-
interview (ACASI); medical history and clinical evaluation
were documented using CAPI; and blood, urine, and vaginal
swabs were obtained. Participants were tested for hemoglobin
and platelet levels, liver and kidney function, STI serologies
(syphilis and genital herpes [HSV-2]), and pregnancy for
women. Rapid HIV testing following the Kenyan national algo-
rithm was conducted with pre- and posttest counseling. Male
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circumcision was verified by physical examination. Laboratory
results were used to make the final study eligibility determina-
tion. Persons were informed of their enrollment eligibility
status 2 weeks following the initial (screening) visit.
Enrollment Criteria
Study enrollment was limited to male and nonpregnant
female residents of the Kisumu catchment area, aged 15
to 64 years. This expanded age range from 18 to 34 years
in KICoS1was used to capture data on the prevalence and
incidence of HIV seroconversion among Kenyans aged 50
to 64 years, an understudied, suspected high-risk population
identified through the Kenya AIDS Indicator Survey 2007.19
This group requires more focus on HIV research studies and
intervention trials as do minors who are pregnant, married,
or have children. Enrollees needed to report being sexually
active within the 3 months prior to enrollment and be HIV
negative but belonging to a ‘‘high-risk group’’ for HIV
acquisition based on the following criteria (derived from
previous HIV prevalence and qualitative studies)2: earned
a living as a commercial sex worker (CSW), truck driver,
car washer, police officer, or in fishing-related activities;
had a regular sexual partner who was HIV infected; was a
widow or widower; was a man who reported having sex
with men (MSM); or was a homeless youth living on the
streets. To be included in enrollment, participants also
needed to answer ‘‘yes’’ in ACASI to acknowledge at least
1 occasion of ‘‘high-risk behavior’’ in the previous 12
months: Did you have a sexual partner who is infected with
HIV? Did you have vaginal or anal sexual intercourse with
an anonymous partner who could not be contacted again?
Did you have vaginal or anal sex in exchange for money,
goods, or services? Did you have vaginal or anal sex with
2 or more partners? Did you have a STI? Additionally, par-
ticipants needed to be (1) willing to undergo an HIV test
and receive results, (2) not to be in another HIV interven-
tion study, (3) willing to give locator information, and (4)
not planning to relocate outside the catchment area within
the following 12 months. Offspring recruits could only be
enrolled in the study if they had a referral card received
from someone else in the referral chain. For those eligible
for cohort study follow-up, a study photoidentification card
with a unique barcode was issued, and detailed locator
information was obtained and later verified by a home visit
by study staff.
Study Incentives
All participants received provision of allowable incentives
(transport reimbursement, bar soap, insecticide-treated mos-
quito net, and exercise book) to minimize loss to follow-up.
Participants received HIV risk-reduction counseling and
condom provision, treatment for common ailments (eg, diar-
rhea, respiratory and skin infections), and referrals for other
services (including medical male circumcision) at all visits.
Follow-Up Procedures
Follow-up visits were scheduled every 3 months for a period of
12 months. At each follow-up visit, multiple activities were
completed, including an ACASI behavioral questionnaire,
rapid HIV testing, and a blood draw for laboratory testing.
Laboratory Procedures
All blood, urine, and vaginal specimens were processed and
tested at the KEMRI/CDC ISO-certified laboratory located at the
KEMRI/CDC facilities in Kisumu.32 Hemoglobin and platelet
counts were done using the Becton, Dickinson and Company
(BD; Franklin Lakes, New Jersey) coulter counter complete
blood count from whole blood, while the liver and kidney func-
tions were analyzed using the ROCHE biochemistry analyzer
from serum (ROCHE Diagnostics, Indianapolis, Indiana). Rapid
HIV testing was conducted using Uni-Gold HIV-1/2, (Trinity
Biotech, Wicklow, Ireland) and Determine HIV-1/2 (Abbott
Labs, Tokyo, Japan) with the Bioline test (Meridian Life Science
Company, Cincinnati, Ohio) as a tiebreaker. Testing for syphilis
was done using BD Micro-Vue Rapid Plasma Reagin cardtest
with all reactive tests confirmed by Serodia TP-PA Syphilis
Test. Herpes simplex virus 2 was detected using KALON
HSV-2 Immunoglobulin G enzyme-linked immunoassay
(Kalon Biologicals Ltd, Surrey, United Kingdom), and urine
pregnancy test was done using First Sign HCG One Step
(UNIMED International, Inc, South San Francisco,
California).
Procedures for HIV-Positive Persons
At screening, individuals who tested HIV-positive were pro-
vided with CD4 count results and referred to HIV care and treat-
ment clinics, as they were ineligible for enrollment. Enrolled
persons who seroconverted during the course of the study were
provided with CD4 count and viral load results, follow-up visits,
counseling, and referrals for HIV care and treatment and were
retained in the study.
Data Analysis
For those screened but not eligible for cohort study enrollment,
HIV prevalence by sex and age was examined. The rate of
increase in prevalence by age for each gender was calculated
using the median age. For those enrolled, demographic and
behavioral characteristics were examined, and age distribu-
tions were compared by sex. Participants who acquired HIV
during the course of the study were characterized by demo-
graphics and risk factors. HIV IRs were calculated based on
1 year of follow-up.
We calculated disease incidence using person-days of obser-
vation in the at-risk population. For enrolled participants,
person-time was computed separately for those who did not
seroconvert during the course of the study and those who did.
Person-days for those who did not serconvert were calculated
as the number of days from the first negative HIV test (ie,
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baseline) to the last negative HIV test. For participants who ser-
oconverted, person-days of observation were calculated as the
number of days from the baseline test date to the date of the last
negative HIV test plus half the number of days between the last
HIV-negative test and the first HIV-positive test. We chose this
midpoint as a crude estimate of the actual time of seroconver-
sion. Person-days were then converted to person-years (py) by
dividing total person days by the number of days in a year
(365.25 days). Participants who dropped out of the study were
accounted for in our calculations of person-time. Subgroup and
overall IRs per 100 py were calculated as the number of new
cases of disease identified within the population (or subgroup)
divided by the total number of py contributed by all patients
within the population (or subgroup).
Demographic and behavioral differences between seed and
offspring recruits were examined. To assess the significance
of these differences, we used the chi-square test for categorical
variables and the Wilcoxon test for continuous variables. A lin-
ear regression analysis was used to test for linear trend in HIV
prevalence by age. SAS version 9.1.3 (SAS Institute, Cary,
North Carolina) was used for all analyses.
Results
Screening and Enrollment
Among the 2205 persons (966 men, 1239 women) presenting for
study consideration, 1347 (61.1%) met study prescreening elig-
ibility criteria. Of the 1292 of 1347 (96%) who completed screen-
ing, 644 persons were enrolled in the study. About three-quarters
(73%) of the women who presented for study consideration were
ineligible (for reasons such as being HIV-positive at baseline, sex-
ual inactivity, pregnancy, or not meeting the high-risk criteria),
reducing the proportion of female enrollees to 51.7%. Very few
(n¼ 83, 6.4%) persons prescreened were less than 20 years of age,
and approximately one-third (n¼ 29, 35%) of persons aged <20
years were not enrolled, resulting in an 8.4% (n ¼ 54) final pro-




















Reasons for exclusions at enrollment (not mutually
exclusive)
338 HIV seropositive (rapid test result)
142 Sexually inactive^ (ACASI self-report)
85 Plan to reside outside catchment area^ (ACASI
self-report)
40 Didn’t show up for enrollment visit
25 Pregnant (urine pregnancy test result)
12 Refusals
12 Significant laboratory abnormalities
3 Significant clinical abnormalities
1 Poor assessment of comprehension
Reasons for exclusions at pre-screening (not mutually
exclusive)
560 Participant not high-risk*
224 Sexually inactive (CAPI self-report)
126 Have been told they are HIV-positive before
120 Plan to reside outside the catchment area
93 Participating in another HIV trial
62 Not willing to receive HIV test results
59 Not willing to have an HIV test
20 Not willing to come for study visits
16 Pregnant (self-report)
7 Not willing to provide detailed locator information





Figure 1. KICOS3 study profile at baseline screening and enrollment. *, not member of a ‘‘high-risk group’’ or did not acknowledge at least 1
‘‘high-risk behavior’’ as defined in methods section. ∧, participants were asked twice, once during prescreening CAPI, another time during
screening ACASI. **, written informed consent sought prior to proceeding with screening procedures. ACASI, Audio Computer-Assisted Self
Interview; CAPI, Computer Assisted Personal Interview; KICOS3, Kisumu Incidence Cohort Study 3.
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initially recruited (seed recruits) and 517 (80.0%) were referrals
(offspring recruits) identified by the seed recruits and by other off-
spring recruits (Figure 1).
Baseline Characteristics of Enrollees
1. Age and sex (Figure 2): while the proportion of the men
and women was approximately equal (48.3% versus
51.7%), enrolled women were significantly older than
men statistically: median age 25 versus 23 years (P <
.01). Women were twice as likely to be aged 30 to 64
years (P < .01) and half as likely to be <20 years (P <
.01). The largest single group (42.5%, n ¼ 274) of the
enrollees was men aged 20 to 24 years. We also
recruited 77 (12%) persons aged 35 to 64 years.
2. Behavioral risks (Table 1): about half (51%) of the
enrollees reported being male and female CSW in the
12 months prior to enrollment, and the remaining half
had a variety of other risk factors. Among the 272
female CSW, 153 (56%) were aged 25 years. In all,
56 (18%) men reported being CSW and 97 (31%) men
were in the MSM category.
About half of the enrolled men (48%) were not circumcised. Of
the enrollees, 79% reported having one or more occurrences of
unprotected vaginal or anal sex and 35% reported treatment for
an STI in the previous 3 months. The most common STI
syndrome for which treatment had been received was genital
ulcer disease (42.6%). Frequencies of reporting unprotected
sex (P ¼ .77) and treatment for an STI (P ¼ .99) were not sig-
nificantly different between the seed and the offspring recruits.
Baseline HIV Prevalence among Screened Persons
The overall HIV prevalence among individuals screened was
26.1% (338 of 1292). Prevalence was nearly 3 times as high
among women as among men: 35.6% (272/765) versus
12.5% (66 of 527; P < .01) and increased by sex with age (P
for trend ¼ .04). The rate of the rise in prevalence per year
of age for a person aged 15 to 29 years was approximately dou-
ble for women compared to men: 1.6% versus 0.8% (P < .01).
Baseline prevalence was 33.1% (236 of 712) in male and
female CSW and 6.9% (9 of 130) in MSM. HIV prevalence
among the seed recruits was similar compared to offspring
recruits: 22.8% (52 of 228) versus 26.9% (286 of 1064; P ¼
.21; Figure 3).
HIV Incidence among the Enrollees
Of the 644 persons who were enrolled and followed for a
period of 1 year, 61 (9.5%) voluntarily withdrew from the
study, resulting in 627 py of follow-up overall (women, 318
py; men, 309 py). Seven of the enrollees seroconverted during
the course of their study participation (IR per 100 py, 1.1;
95% CI: 0.45-2.30). Of the 7 incident cases, 6 (86%)
occurred among women, 5 of whom were aged 20 to 25
years. CSWs accounted for 5 (83%) of the 6 cases among
women. The single male seroconverter was a 26-year-old
MSM CSW who was not circumcised. HIV-seroconversion
among female CSW aged 25 years was significantly higher
(5 of 153, 3.3% versus 0 of 21, 0%, P < .01) compared to
female nonsex workers aged 25 years. The distribution of
seed and offspring recruits among cases (seed:offspring ratio
¼ 1:3.5) was similar to their relative proportions in the study
population (seed:offspring ratio ¼ 1:4). The HIV IR was 1.88
(95% CI: 0.69-4.10) per 100 py among women overall, 3.14
(95% CI: 1.02-7.34) per 100 py among women aged 25,
4.21 (95% CI: 1.36-9.82) per 100 py among women aged 20
to 24 years, 1.90 (95% CI: 0.69-4.11) per 100 py among male
and female CSW, 1.03 per 100 py (95% CI 0.03-5.79) among
MSM, and 0.32 (95% CI: 0.01-1.80 per 100 py among men
(Table 2).
Discussion
This study cast a broad net attempting to identify an urban pop-
ulation with a high HIV incidence suitable for HIV prevention
trials in western Kenya. As a result of the effort to focus on
those at the highest likelihood of prevalent or incident HIV
Figure 2. Age distribution of enrolled participants by sex, KICOS3
2010 to 2011 (N ¼ 644). The horizontal lines at the top show the age
distribution of the study participants. The arrow indicates the median
age (years); the numbers at the ends of the horizontal line are the 25th
(left) and 75th (right) percentiles; and the length of the line is the
interquartile distance around the median. KICOS3, Kisumu Incidence
Cohort Study 3.
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by expanding the recruitment age from 15 to 34 years (in
KICOS1) to 15 to 64 years and changing the targeted risk
groups, more than 50% of the persons screened did not meet
enrollment criteria. Baseline HIV prevalence among the study
participants was high (26% overall, rising to nearly 50% among
women aged >29 years), suggesting that we were successful in
identifying persons from communities with a high burden of
HIV. Furthermore, the ACASI results confirmed that the
enrolled participants reported multiple risk factors (eg, treat-
ment for an STI in the previous 3 months, unprotected sex,
multiple sex partners, sex with known/suspected HIV infected
persons, and sex with partners of unknown HIV status). Despite
this, the overall HIV cumulative incidence in the cohort after 1
year follow-up was 1.1% (or IR¼ 1.1 per 100 py), considerably
lower than the 3% to 6% levels commonly targeted for success-
ful HIV intervention trials. Review of HIV positivity patterns
in the screened group suggests, however, that the observed inci-
dence should not have been entirely surprising. The rate of rise
in HIV prevalence per year of age in the screened group at
baseline was quite similar to the observed incidence during the
1 year follow-up: 1.6% versus 1.9% for women and 0.8% ver-
sus 0.3% for men, respectively. Of the 7 persons, 6 who sero-
converted during the study were women, 5 of whom were
aged 25 years, a pattern of risk consistent with prevalence
patterns among women in the screened group. These 5 young
women were also engaged in CSW, a factor identified as a risk
factor for HIV acquisition in low- and middle-income
countries.24
Table 1. Baseline Characteristics of Enrolled Participants, KICOS3 2010 to 2011.a
Characteristic
Enrolled Participants
Total N ¼ 644, n (%)
Men
n ¼ 311, n (%)
Women
n ¼ 333, n (%)
Risk category
Commercial sex workers 328/639 (51.3) 56 (18.0) 272 (81.7)
Men who have sex with men 97/639 (15.2) 97 (31.2) –
Fisherfolk 102/639 (16.0) 94 (30.2) 8 (2.4)
Transport (drivers) 34/639 (5.3) 25 (8.0) 9 (2.7)
HIV-negative member of discordant couples (self-report) 11/639 (1.7) 3 (1.0) 8 (2.4)
Widows/widowers 28/639 (4.4) 3 (1.0) 25 (7.5)
Street youth 23/639 (3.6) 23 (7.4) 0 (0.0)
Police 9/639 (1.4) 6 (1.9) 3 (0.9)
Car washers 7/639 (1.1) 4 (1.3) 3 (0.9)
Marital status
Married/living as married 203/640 (31.7) 129/309 (41.7) 74/331 (22.4)
Single/divorced/separated/widowed 437/640 (68.3) 180/309 (58.3) 257/331 (77.6)
Highest level of schooling completed
Primary 243/591 (41.1) 92/290 (31.7) 151/301 (50.1)
Secondary 250/591 (42.3) 124/290 (42.8) 126/301 (41.9)
Postsecondary 98/591 (16.6) 74/290 (25.5) 24/301 (8.0)
STIs
Reported being treated for an STI in the past 3 months 58/166 (34.9) 36/106 (34.0) 22/60 (36.7)
HSV-2, positive 244/573 (42.6) 69/275 (25.1) 175/298 (58.7)
Syphilis, positive 2 (0. 3) 1 (0.3) 1 (0.3)
Sexual risk behaviors in the past 3 months
Number of sex partners, median (IQR) 4 (3-8) 4 (3-8) 5 (3-8)
Unprotected sex 509 (79.0) 267 (85.6) 242 (72.7)
Sex with known/suspected HIV infected partner 209 (32.5) 99/262 (37.8) 110/272 (40.4)
Sex with partner of unknown HIV status 461 (71.6) 178/220 (81.0) 175/241 (72.6)
Circumcised (men only) 162 (52.1)
Abbreviations: IQR, interquartile range; KICOS3, Kisumu Incidence Cohort Study 3; STI, sexually transmitted infection; HSV-2, Herpes simplex virus 2.
a Fractions are included to show missing values.
Figure 3. Baseline HIV prevalence by sex and age group among
screened participants, KICOS3 2010 to 2011 (N ¼ 338/1292).
KICOS3, Kisumu Incidence Cohort Study 3.
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These results suggest that the apparently paradoxical finding
of high prevalence and comparatively low incidence may have
a relatively simple explanation. In our study, prevalence was
nearly 3 times as high among women as among men, con-
firming similar findings previously reported in Kenya.28,33
Among both men and women, prevalence steadily rose with
age, consistent with other studies in the same locality. These
prevalence data suggest that demographically the group with
highest incidence would be younger women. Most of our
incident cases occurred among women 25 years of age,
among which the IR was 3.1 per 100 py. Nevertheless, this
group only constituted 23% of our study population. Women
had constituted >60% of the initial recruits, but two-thirds
of them were excluded (for reasons, at baseline, such as
being pregnant, HIV-seropositive, sexually inactive, or not
being considered high risk), so that the proportions of men
and women among enrollees ended up approximately equal.
In addition, study women were significantly older than the
men: less than 10% of our population was aged <20 years,
and women were half as likely as men to be in this age
group. The largest single group constituting almost half the
enrolled population was men aged 20 to 24 years, who
would be expected to have low incidence and, in fact, had
no seroconversions. Expanding our upper age eligibility to
64 years to study incidence in older age groups may have
also contributed to the low yield.
Our study has a number of limitations. We depended
upon the self-report for our behavioral indicators, and the
validity of self-report about sexual behavior has been called
into question.5 Study participation can be very attractive to
potential participants for multiple social, financial, and asso-
ciated reasons, resulting perhaps in exaggeration or even
impersonation of high-risk status.34 Participants involved
in snowball or respondent-referral sampling studies (like
KICoS3) may also be inclined to refer persons who are not
actually from the same risk groups as they are, either for
their own benefit or for the benefit of the offspring partici-
pants.30 We offered study participants a standard package of
counseling and condoms, so that incidence observed in the
study may have been lower than it might have been other-
wise, a common occurrence in HIV incidence studies that
offer HIV prevention services.13 We followed a small study
cohort for a relatively short duration (1 year) and had a 10%
dropout rate, which may also have affected results. The
small number of our incident cases makes any comparison
of the incident to the nonincident cases difficult. Finally,
due to the types of rapid HIV testing used in this study, the
exact timing of seroconversion (which may have ranged
within a month of testing positive) for each of the 7 cases
could not be accurately determined. We did not ascertain
how many of the individuals who were ineligible due to
being HIV seropositive were recently infected. Therefore,
the number of high-risk individuals who were screened but
not enrolled could include recent incident cases which
would have increased the number of incident HIV
infections.
Despite our population’s self-reported behavioral risks for
HIV acquisition, the overall rate of rise in age-specific preva-
lence in our study is fairly similar to that found by other studies
in the same province.28,33 Unlike in the United States, HIV
transmission in Africa is generalized; the risk for HIV infection
in high-prevalence areas like Kisumu, as indicated by our
results, may most easily be captured by simply targeting the
factors of sex, age, and CSW. Our findings, consistent with
suggestions from other population-based studies in sub-
Saharan Africa, suggest that young women aged 25 years
attending venues similar to those we sampled from are prime
candidates for prevention programs and intervention trials
aimed at interrupting HIV transmission in western Kenya, and
indeed in other parts of Africa with high HIV prevalence.
Future prevention trials in urban centers should target this
vulnerable group.
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1 Female 38 Sex worker Seed Positive
2 Female 22 Sex worker Seed Negative
3 Male 26 Men who have sex with men Offspring Positive
4 Female 23 Sex worker Offspring Positive
5 Female 25 Sex worker Offspring Indeterminate
6 Female 24 Sex worker Offspring Positive
7 Female 24 Widow Offspring Negative
Abbreviations: KICOS3, Kisumu Incidence Cohort Study 3; STI, sexually transmitted infection; HSV-2, Herpes simplex virus 2.
a N ¼ 7.
b N ¼ 644.
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